08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: An undetermined target

Infectious disease INDICATION: Enterovirus Cell culture studies identified four diarylhydrazide-based compounds that could help treat enteroviral infection. Chemical synthesis of diarylhydrazide analogs and testing in human muscle cell-based assays yielded four compounds that inhibited enterovirus...
02:48 , Feb 2, 2016 |  BC Extra  |  Financial News

Sinovac mulls take-private proposal

Sinovac Biotech Ltd. (NASDAQ:SVA) gained $0.78 (16%) to $5.80 on Monday after it received a non-binding proposal from President and CEO Weidong Yin and existing shareholder SAIF Partners to acquire all outstanding shares of the...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

EV71 vaccine regulatory update

Sinovac said the China Food and Drug Administration (CFDA) issued a new drug certificate and production license for the company’s EV71 vaccine against hand, foot and mouth disease (HFMD) caused by human enterovirus 71 (EV71)....
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Sinovac infectious news

Sinovac said it was awarded a RMB60 million ($9.6 million) grant to construct a production facility for its human enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). The award came from China's...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Clinical News

EV71 vaccine: Final Phase III data

Last May, Sinovac reported top-line data from the trial (see BioCentury, May 18, 2013). Sinovac said an NDA for the vaccine is under review by China's Food and Drug Administration (CFDA). Sinovac Biotech Ltd. (NASDAQ:SVA),...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Transgenic scavenger receptor class B member 2 (SCARB2) mice to model enterovirus 71 (EV71) neuropathogenesis Transgenic mice that express human SCARB2 could be useful for...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

EV71 vaccine regulatory update

Sinovac said the Beijing Drug Administration (BDA) accepted for review an NDA for its EV71 vaccine against hand, foot and mouth disease (HFMD) caused by human enterovirus 71 (EV71). Sinovac said that under current regulations...
07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $12.74 (21%) to $72.83 last week after at least two analysts raised their price targets on the stock and EMA's CHMP backed approval of an MAA for Lojuxta...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Inviragen, Takeda deal

Takeda will acquire infectious disease company Inviragen for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's DENVax , a recombinant tetravalent attenuated live dengue vaccine , is in Phase...
01:10 , May 9, 2013 |  BC Extra  |  Company News

Takeda acquiring Inviragen

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire infectious disease company Inviragen Inc. (Fort Collins. Colo.) for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's DENVax , a recombinant tetravalent...